CMS Administrator Dr. Oz proposes deep cuts to the 340B drug program to lower Medicare costs. Learn how this affects ...

CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...

The rule, released Thursday, builds on Trump administration’s priorities, including cutting Medicare reimbursement for drugs ...

CMS would set 340B drug payment at ASP–33.4%, lowering Medicare and beneficiary drug outlays while redistributing equivalent ...

The Centers for Medicare and Medicaid Services’ annual outpatient hospital pay increase proposal has come with a potential ...

A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing policy debate.

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

The 340B program helps rural hospitals like Cookeville Regional provide affordable care to vulnerable patients.

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

The Trump administration is considering a pilot program that could bring much-needed transparency to the 340B drug discount program, created by Congress to help hospitals and clinics serving ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...